The Journal of infectious diseases · 2026
Detection of Marburg Virus Antibodies 25 Years After Outbreak in Watsa, Democratic Republic of the Congo.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Merritt Sydney, Mukadi Patrick K, Kompany Jean Paul, Halbrook Megan, Musene Kamy, Martin Skylar A, Beya Michael, Tambu Merly, Wong Teri Ann S, Muyembe-Tamfum Jean Jacques, Kaba Didine K, Lehrer Axel T, Kindrachuk Jason, Hoff Nicole A, Mbala-Kingebeni Placide, Rimoin Anne W
Аннотация
BACKGROUND: To date, 18 Marburg virus disease (MVD) outbreaks have been reported, most recently in Tanzania and Ethiopia. From 1998 to 2000, a large MVD outbreak in Watsa/Durba region, Democratic Republic of the Congo (DRC), resulted in 154 cases and 128 deaths. Given the public health risks posed by MARV, the lack of approved vaccines and therapeutics, and unpredictability of future outbreaks, this study aimed to assess the anti-MARV seroprevalence in Watsa/Durba.
METHODS: Samples collected in May 2023 (n = 313) included known MVD survivors (n = 5), close contacts (n = 22), and other residents (n = 286). A multiplexed immunoassay was used to assess seroreactivity to MARV and other pan-filovirus targets.
RESULTS: Among the Watsa/Durba cohort, 4.5% and 1.6% were seroreactive to MARV glycoprotein (GP) and VP40, including only 1 known MVD survivor. No significant associations were found between MARV seroreactivity and risk factors: travel to Uganda, receiving injections, or employment as a gold miner. Of those 14 MARV GP-reactive individuals, 85.7% were cross-reactive to other filoviral targets.
CONCLUSIONS: This detected seroprevalence among individuals with no known exposure history may indicate continued exposure to MARV or MARV-like antigens 25 years after the conclusion of the outbreak; cross-reactivity to pan-filovirus targets further suggest the potential for undetected cases.
METHODS: Samples collected in May 2023 (n = 313) included known MVD survivors (n = 5), close contacts (n = 22), and other residents (n = 286). A multiplexed immunoassay was used to assess seroreactivity to MARV and other pan-filovirus targets.
RESULTS: Among the Watsa/Durba cohort, 4.5% and 1.6% were seroreactive to MARV glycoprotein (GP) and VP40, including only 1 known MVD survivor. No significant associations were found between MARV seroreactivity and risk factors: travel to Uganda, receiving injections, or employment as a gold miner. Of those 14 MARV GP-reactive individuals, 85.7% were cross-reactive to other filoviral targets.
CONCLUSIONS: This detected seroprevalence among individuals with no known exposure history may indicate continued exposure to MARV or MARV-like antigens 25 years after the conclusion of the outbreak; cross-reactivity to pan-filovirus targets further suggest the potential for undetected cases.